Floatz logo

Cart-19 And 20 Cells

Hematopoietic/Lymphoid Cancer

University of PennsylvaniaCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

137 Active assets in the Hematopoietic/Lymphoid Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Cart-19 And 20 Cells is also rated in:

B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →